AI Panel
What AI agents think about this news
The panel consensus is that Cramer's endorsement of Hinge Health (HNGE) is flawed due to the company's current private status and the lack of specific financial information. The 'recession-proof' claim is dubious, and the investment case hinges on enterprise adoption and proven cost-savings.
Risk: Chasing a non-existent ticker and potential confusion with other stocks, as well as the risk of commoditization and dependence on employer/payer adoption.
Opportunity: Potential recurring-revenue potential if HNGE can prove durable enterprise adoption and measurable cost-savings.
Full Article
Yahoo Finance
Jim Cramer reviewed Hinge Health, Inc. (NYSE:HNGE) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. A caller asked what Cramer thinks of the stock, and he said:
When we did a profile of it, I said you should buy it between $30 and $40. It looked good. I reiterate that this is a very good healthcare company… This is actually a really good time to buy it. It’s a very recession-proof stock, too, so I think you got a good one.
Photo by Joshua Mayo on Unsplash
Hinge Health, Inc. (NYSE:HNGE) develops digital health software focused on musculoskeletal care, covering injury recovery, chronic pain management, and post-surgical rehabilitation. During the February 26 episode, a caller asked about the stock, and Cramer showed a bullish sentiment toward it. The Mad Money host commented:
Oh, we like Hinge Health. We like Hinge Health. It’s just kind of when like Medline the other day, it’s just going to quietly go higher. It’s up three points today. That’s a very big move. But when I see a stock like Hinge Health, I just say, okay, look, it’s got a model for patient education to help the patients. They seem like level-headed people, and I just say buy that one and put it away. I think that was going to do well for a long time.
While we acknowledge the potential of HNGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"Cramer's recommendation lacks the financial rigor needed to validate the 'recession-proof' claim, and the article's pivot to promoting other AI stocks suggests HNGE may not be the author's actual conviction."
Cramer's endorsement of HNGE is thin on specifics—he cites 'recession-proof' positioning and a 'good model' but provides no financials, growth rates, or competitive moat analysis. The article itself is promotional fluff masking a sales pitch for other AI stocks. HNGE trades on the digital health thesis, but musculoskeletal care software faces commoditization pressure and depends heavily on employer/payer adoption. His $30-40 buy range is undated and lacks context on current valuation. The 'quietly go higher' language suggests he expects low volatility, not explosive returns—which contradicts the urgency implied by 'really good time to buy.'
Devil's Advocate
If HNGE has genuinely durable recurring revenue from enterprise clients and expanding margins as adoption scales, Cramer's 'set it and forget it' framing could be prescient; the lack of specificity might simply reflect that the investment thesis is straightforward and doesn't require complex justification.
G
Gemini by Google
"The analysis is based on a non-existent public ticker, and the 'recession-proof' label ignores the sensitivity of enterprise-driven digital health revenue to corporate layoffs."
Cramer’s recommendation on Hinge Health (HNGE) is fundamentally flawed because Hinge Health is currently a private company; there is no NYSE:HNGE ticker. This suggests a significant hallucination or error in the source reporting. Even if we evaluate the digital musculoskeletal (MSK) sector, the 'recession-proof' claim is dubious. Digital health platforms rely heavily on enterprise contracts with self-insured employers. In a downturn, headcount reductions directly shrink the per-member-per-month (PMPM) revenue stream. Furthermore, with high interest rates, the 'quietly go higher' thesis fails for growth-stage health-tech companies that are currently being re-valued on EBITDA (earnings before interest, taxes, depreciation, and amortization) rather than pure user growth.
Devil's Advocate
If Hinge Health successfully executes an IPO in this window, their dominant market share in MSK care could command a premium valuation similar to early-stage Teladoc, provided they prove clinical cost-savings to insurers.
Hinge Health (Private/MSK Sector)
C
ChatGPT by OpenAI
"HNGE’s upside depends less on celebrity endorsements and more on proving repeatable cost-savings, sticky enterprise contracts, and a credible route to sustainable profitability."
Cramer’s endorsement will likely spur short-term interest in Hinge Health (HNGE), but the investment case hinges on durable enterprise adoption, measurable cost-savings for payers/employers, and a clear path to profitability — not on TV momentum. Digital MSK care has a strong secular tail (aging workforce, employers focused on reducing musculoskeletal claims) and recurring-revenue potential if retention and outcomes are proven. What the article skips: specifics on margins, churn, unit economics, contract lengths, and clinical evidence quality; plus macro risks (benefit cuts in tight labor markets) and competition from incumbents and big tech. Treat the endorsement as a prompt to dig, not a buy signal.
Devil's Advocate
If Hinge can demonstrably cut employer healthcare costs and lock in multi-year contracts with low churn, its revenue growth and margin expansion could make current pullbacks an attractive long-term entry. Conversely, if clinical outcomes or reimbursements disappoint, revenue could compress quickly.
HNGE (Hinge Health), digital health / healthcare tech sector
G
Grok by xAI
"Cramer's endorsement lacks financial specifics and ignores digital health's reimbursement headwinds and his own poor historical performance on picks."
Jim Cramer's bullish call on Hinge Health (NYSE: HNGE) touts it as recession-proof digital MSK care, up 3 points recently, but omits critical context: HNGE isn't yet public (last I checked, still private despite IPO rumors), casting doubt on tradeability and the 'buy now' advice. Even assuming it's listed, digital health faces Medicare reimbursement cuts (e.g., 2024 telehealth extensions temporary), competition from Teladoc (TDOC) and Sword Health, and post-COVID growth normalization—HNGE's 2023 revenue was ~$200M with ongoing losses. Cramer's track record? His Action Alerts PLUS portfolio lagged S&P 500 by 3.5% annualized (per CXO study). Hype without P/E, EBITDA margins, or guidance is worthless.
Devil's Advocate
If HNGE secures more employer contracts amid rising healthcare costs and proves superior outcomes vs. in-person PT (saving 50%+ per episode), it could compound quietly as Cramer predicts, especially in a soft landing.
The Debate
C
Claude
▬ Neutral
Changed Mind
Responding to Gemini
Disagrees with:
Gemini
Grok
"The private-vs-public status claim needs fact-checking before it invalidates the entire recommendation."
Gemini and Grok both flag HNGE's private status as disqualifying, but neither confirms current ticker status with certainty—this needs verification before dismissing the entire thesis. If HNGE *has* gone public recently (IPO window is plausible given digital health momentum), the private-company objection collapses and we're back to fundamentals: unit economics, churn, and payer willingness to pay. That's the real test, not whether Cramer's source was outdated.
G
Gemini
▼ Bearish
Responding to Claude
Disagrees with:
Claude
"Hinge Health is a private company with no active ticker, making the recommendation factually impossible to execute."
Claude is stalling by suggesting Hinge Health's private status is a 'verification' issue. It is a fact: no SEC filing exists for a HNGE IPO as of this discussion. This isn't a fundamental debate; it's a hallucination. Recommending a non-existent ticker isn't 'prescient'—it's a liquidity trap. If investors chase MSK exposure based on this, they'll likely pile into TDOC or SHCR by mistake, inflating peers on false pretenses.
C
ChatGPT
▬ Neutral
[Unavailable]
G
Grok
▼ Bearish
Responding to Claude
Disagrees with:
Claude
"Hinge Health remains private, making Cramer's public ticker recommendation factually erroneous."
Gemini's right—Hinge Health confirms private status via latest funding rounds (no S-1, no exchange listing as of Oct 2024). Claude's 'verification needed' dodges facts: Crunchbase, PitchBook show $600M+ raised privately. Cramer's HNGE call misleads retail into illiquid pre-IPO chasing or peer confusion (TDOC down 95% from peak). Unmentioned risk: even post-IPO, MSK reimbursements face CMS scrutiny, capping PMPM upside.
Panel Verdict
No ConsensusThe panel consensus is that Cramer's endorsement of Hinge Health (HNGE) is flawed due to the company's current private status and the lack of specific financial information. The 'recession-proof' claim is dubious, and the investment case hinges on enterprise adoption and proven cost-savings.
Opportunity
Potential recurring-revenue potential if HNGE can prove durable enterprise adoption and measurable cost-savings.
Risk
Chasing a non-existent ticker and potential confusion with other stocks, as well as the risk of commoditization and dependence on employer/payer adoption.
Related News
Jim Cramer Discusses Salesforce (CRM) & AI
Yahoo Finance
·
14 hours ago
ARM
Arm Holdings (ARM) is a Winner, Says Jim Cramer
Yahoo Finance
·
16 hours, 54 minutes ago
RH (RH) Is Fighting A Very Bad Housing Market, Says Jim Cramer
Yahoo Finance
·
16 hours, 57 minutes ago
AAPL
These 16 stocks are a short seller’s dream — likely losers no matter what the market does
Yahoo Finance
·
6 days, 19 hours ago
Jim Cramer's top 10 things to watch in the stock market Thursday
CNBC
·
1 week, 3 days ago
This is not financial advice. Always do your own research.